Burning Rock Biotech Limited revised revenue guidance for full year of 2022. For full-year revenue growth for 2022 to be approximately 10% compared to that of 2021. This represents an upward revision compared with the CompanyÃs previous guidance on the full-year revenue growth of 5% as announced on November 15, 2022 in its financial results for the third quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 USD | -7.38% |
|
+9.20% | -29.78% |
1st Jan change | Capi. | |
---|---|---|
-29.78% | 6.7Cr | |
-16.83% | 861.62Cr | |
+79.26% | 460.49Cr | |
+15.95% | 298.45Cr | |
-3.15% | 265.8Cr | |
-4.20% | 197.95Cr | |
-52.37% | 190.76Cr | |
-13.53% | 155.56Cr | |
+21.59% | 125.05Cr | |
-47.00% | 107.66Cr |
- Stock Market
- Equities
- BNR Stock
- News Burning Rock Biotech Limited
- Burning Rock Biotech Limited Revises Revenue Guidance for Full Year of 2022